Tandem Diabetes Care offers 56.8% analyst-implied upside with three of the last four quarters showing earnings beats and improving EPS surprises, but a quality score of 3.1 below the investment floor, 23% short interest, and a single critical supplier dependency on Unomedical make this a high-risk setup.
Thesis pillars
- High Analyst Upside Recovery→Stable
- Improving Earnings Beat Pattern→Stable
- Below Floor Quality Cash Burn↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 19, 2026· older than 90 days
Tandem Diabetes Care, Inc. (TNDM) Stock Analysis
Momentum Cont setup · Inst Constrain edge
Healthcare · Medical Devices
Sell if holding. Engine safety override at $19.05: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 2.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Elevated put/call ratio: 86.60; Below-average business quality.
Tandem Diabetes Care develops and commercializes insulin pump systems under the t:slim X2 and Tandem Mobi brands, with Control-IQ+ AID technology, serving nearly 500,000 people across more than 25 countries. Revenue is generated from pump sales and recurring single-use supplies... Read more
Sell if holding. Engine safety override at $19.05: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 2.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Elevated put/call ratio: 86.60; Below-average business quality. Chart setup: Trend continuation, RSI 66, MACD bullish. Score 5.6/10, moderate confidence.
Passes 6/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: aggressive.
About Tandem Diabetes Care, Inc.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care commercializes two insulin pump platforms — the t:slim X2 and Tandem Mobi — both featuring Control-IQ+ automated insulin delivery technology cleared by the FDA in March 2025 for type 2 patients aged 18 and older, building on its type 1 clearance for patients aged 2 and older. The company assembles pumps at its San Diego, California facility and serves nearly 500,000 people in more than 25 countries. Mobi with Android control launched in December 2025, extending the platform further.
Revenue comes from durable pump sales and recurring single-use supplies — insulin cartridges and infusion sets replaced every three to seven days. In the U.S. and Canada, distribution runs through independent distributors for order fulfillment while Tandem's own sales, clinical, and customer support teams manage the patient relationship. The company is transitioning toward a pharmacy benefit reimbursement model as an alternative to the traditional durable medical equipment channel, which could reduce upfront pump payments while increasing recurring supply revenue per customer. Unomedical A/S, a ConvaTec subsidiary, manufactures all commercially marketed infusion sets as a sole-source supplier. Two independent distributors each represented more than 10% of worldwide 2025 sales. Competitors include Insulet, Medtronic, Beta Bionics, mylife, and Sequel.
Show full overview
The FDA's December 2025 finalization of competitive bidding for insulin pumps and continuous glucose monitors under CMS — alongside a proposed shift to monthly rental reimbursement — introduces structural pricing pressure to Tandem's U.S. durable medical equipment channel. The company's ACE pump and iAGC classification under FDA Class II special controls provides a streamlined regulatory path but requires ongoing satisfaction of those controls, or products revert to the full PMA process. Tandem also depends on CGM integrations with Dexcom and Abbott, which can be terminated on relatively short notice; in May 2026, the company terminated Chief Commercial Officer Mark Novara without cause, leaving the commercial leadership role vacant.
See also: Healthcare · Medical Devices
From Tandem Diabetes Care, Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated Oct 30, 2026Recent Developments — Tandem Diabetes Care, Inc.
Latest news
- NEWS Tandem Diabetes Care Announces Upcoming Conference Presentations — fiscal.ai Oct 30, 2026 neutral
- NEWS Tandem Diabetes Care Q2 2026 Earnings Call Transcript — benzinga Oct 12, 2026 neutral
- NEWS Barclays Initiates Coverage On Tandem Diabetes Care with Equal-Weight Rating, Announces Price Target of $18 — benzinga Oct 7, 2026
- NEWS Citigroup Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $20 — benzinga Sep 30, 2026 neutral
- NEWS Tandem Expands Mobi Availability To 12 International Markets, Pairing Control-IQ+ Predictive Algorithm, Studied In Type — benzinga Sep 28, 2026 positive
Latest item Oct 30, 2026 · Generated 2026-11-05T11:49:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- LOWCustomertwo independent distributors >10%10-K Item 1: 'two independent distributors each accounted for more than 10% of our worldwide sales'
- HIGHSupplierUnomedical A/S10-K Item 1: 'we purchase all of our currently marketed infusion sets from a third-party supplier, Unomedical A/S, a subsidiary of the ConvaTec Group'
Material Events(8-K, last 90d)
- 2026-05-21Item 3.03LOWStockholders at May 20, 2026 annual meeting approved charter amendments to allow director removal with or without cause (DGCL §141(k)) and to limit officer liability (DGCL §102(b)(7)). Amended charter filed with Delaware Secretary of State on May 21, 2026.SEC filing →
- 2026-05-15Item 5.02MEDIUMMark Novara, EVP and Chief Commercial Officer, notified May 11, 2026 of termination without cause; last day May 18, 2026. No successor named. Company stated strategy and 2026 goals remain unchanged.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Volatile — 5.3% daily ATR makes tight stops impractical. Position-size conservatively.static
Unprofitable operations — net margin -6.1%. Quality floor flags this regardless of sector context.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $19.05: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.6/10 and A.R:R 2.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Elevated put/call ratio: 86.60; Below-average business quality. Chart setup: Trend continuation, RSI 66, MACD bullish. Prior stop was $17.72. Score 5.6/10, moderate confidence.
Analyst target: $24.99 (+31.2% upside). Prior stop was $17.72. Stop-loss: $17.72.
Concentration risk — Supplier: Unomedical A/S; Quality below floor (3.1 < 4.0).
Tandem Diabetes Care, Inc. trades at a P/E of N/A (forward 119.8). TrendMatrix value score: 7.2/10. Verdict: Sell.
30 analysts rate TNDM, with a consensus score of 3.8/5. 21 analysts publish price targets averaging $28.
What does Tandem Diabetes Care, Inc. do?Tandem Diabetes Care develops and commercializes insulin pump systems under the t:slim X2 and Tandem Mobi brands, with...
Tandem Diabetes Care develops and commercializes insulin pump systems under the t:slim X2 and Tandem Mobi brands, with Control-IQ+ AID technology, serving nearly 500,000 people across more than 25 countries. Revenue is generated from pump sales and recurring single-use supplies (cartridges and infusion sets) distributed through independent distributors; two distributors each exceeded 10% of 2025 worldwide sales.